Sofosbuvir: Phase III data

Gilead reported top-line data from 647 non-cirrhotic, treatment-naive patients with chronic HCV genotype 1 infection in the open-label, U.S. Phase III ION-3 trial evaluating a once-daily, oral fixed-dose combination of 400 mg sofosbuvir plus 90 mg ledipasvir with or without ribavirin

Read the full 410 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE